Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05803-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Zhiyuan Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Axitinib, Carcinoma, Renal Cell, Kidney Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sailing Project of "Scientifc and Technological Innovation Action Plan" of Shanghai Science and Technology Commission, Youth Fund of Zhongshan Hospital, Fudan University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
Immune checkpoint inhibitors (ICIs) plus tyrosine kinase inhibitors (TKIs) has become first-line therapy for metastatic renal cell carcinoma patients. This study aims to investigate the effect of tumor infiltrating B lymphocytes (TIBs) on the combination therapy.
Methods
The retrospective analysis was conducted on the clinical records of 115 metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib between March 2020 and June 2023. Observation target: objective response rate (ORR), and overall survival (OS), progression-free survival (PFS) and immune profile.
Results
Patients with high TIBs portended lower ORR of the combination therapy (p = 0.033). TIBs was an independent predictor for poorer OS (p = 0.013) and PFS (p = 0.021) in mccRCC patients with combination treatment. TIBs infiltration was associated with more CD4 + T (p < 0.001), CD8 + T (p < 0.001), M2 macrophages (p = 0.020) and regulatory T cells (Tregs) (p = 0.004). In TIBs high patients, the percentages of PD-1, CTLA-4 and TIM-3 positive rate were significantly increased in CD4 + T (p = 0.038, 0.029 and 0.002 respectively) and CD8 + T cells (p = 0.006, 0.026 and < 0.001 respectively).
Conclusions
Our study revealed TIBs infiltration predicted adverse outcomes in mccRCC patients treated with anti-PD-1 antibody plus Axitinib. As a corollary, TIBs positively associated with M 2 macrophages and Tregs, leading to subsequent multiple immune checkpoints related exhaustion of T cells. Thus, only PD-1 blockade are inadequate to reverse T cells exhaustion effectively in high TIBs mccRCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, China.
- Clinical Center for Biotherapy, Zhongshan Hospital, Fudan University, Shanghai, China. lu.lili@zs-hospital.sh.cn.
Förderung
- Sailing Project of "Scientifc and Technological Innovation Action Plan" of Shanghai Science and Technology Commission
- Youth Fund of Zhongshan Hospital, Fudan University
- National Natural Science Foundation of China
- Sailing Project of “Scientifc and Technological Innovation Action Plan” of Shanghai Science and Technology Commission
Zitieren
APA
Lin, Z., Xiao, S., Qi, Y., Guo, J., & Lu, L. (2024). Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05803-5
Vancouver
Lin Z, Xiao S, Qi Y, Guo J, Lu L. Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05803-5
BibTeX
@article{Lin2024,
author = {Lin, Zhiyuan and Xiao, Shuxiu and Qi, Yu and Guo, Jianming and Lu, Lili},
title = {Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05803-5}
}
EUVIMED